The thesis

AstraZeneca PLC operates in the biopharmaceutical sector with a gross margin of 7927.0% and revenue growth of 6.4% YoY. The company's conviction score is 29/100, indicating a medium conviction tier. Analyst consensus rating is BUY, with a P/E of 23.6x. The high margins and steady revenue growth make the setup interesting.

Why now

The current macro context of inflation fears, as seen in $98 Brent prices, makes AstraZeneca PLC's stable revenue growth more attractive. The company's high gross margin of 7927.0% provides a buffer against potential inflation-driven cost increases.

What to watch

Upcoming revenue growth announcements and any changes in analyst consensus ratings will be key indicators of the thesis's validity. The company's ability to maintain its high gross margin in the face of inflation will also be crucial to watch.

Key risks

Valuation risk is present with a P/E of 23.6x, which may be sensitive to changes in interest rates or market sentiment. Execution risk is also relevant, as the company's revenue growth is steady but not accelerating, at 6.4% YoY.

Theme exposure